Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scanner could halve repeat breast cancer surgeries

NCT ID NCT07527468

Not yet recruiting Symptom relief Sponsor: Hôpital du Valais Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a special scanner that lets surgeons check, in real time during breast cancer surgery, whether all cancer has been removed. The goal is to reduce the need for a second operation. About 228 women with certain high-risk breast cancer types will take part. The scanner is already approved for use, and this study will see if it cuts the repeat surgery rate from about 11% to 5% or less.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Histolog Scanner (a confocal fluorescence microscopy device used during surgery to check if all cancer has been removed)
What this could lead to
If successful, this device could help surgeons remove all cancer in one operation, reducing the need for a second surgery and its associated stress and recovery time.
What could go wrong
This is a relatively small, single-center study comparing results to past cases, not a randomized trial. The device may not work as well in all patients or tumor types, and the final decision for reoperation is made independently, so the device's impact may be limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Carcinoma, Lobular ductal breast carcinoma in situ invasive ductal breast carcinoma invasive lobular breast carcinoma Margins of Excision

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST NEOPLASM FEMALE DUCTAL CARCINOMA IN SITU INVASIVE LOBULAR CARCINOMA

Contacts and locations

Locations

  • Centre Hospitalier du Valais Romand (CHVR)

    Sion, Valais, 1950, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.